| Dr Rami Rustum, MD | |
|
280 Merrimack St, Suite 103, Lawrence, MA 01843-1779 | |
| (978) 685-2455 | |
| (978) 685-2459 |
| Full Name | Dr Rami Rustum |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 30 Years |
| Location | 280 Merrimack St, Lawrence, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881694180 | NPI | - | NPPES |
| 202705274 | Other | MA | TRICARE |
| 30204215 | Medicaid | NH | |
| 1181899 | Other | AETNA | |
| 97211605 | Other | MA | NETWORKHEALTH |
| AA52428 | Other | HPHC | |
| 000000032259 | Other | HEALTHNET | |
| 202705274 | Other | UNICARE | |
| 6126042 | Other | CIGNA | |
| J25828 | Other | BCBS | |
| 203722881 | Other | UHC | |
| AA64187 | Other | HPHC | |
| 0039262 | Other | NHP | |
| 1881694181 | Other | MA | BMC |
| 97211603 | Other | MA | NETWORK HEALTH |
| 003715 | Other | SR WHOLE HEALTH | |
| 1881694180 | Other | BMC | |
| 213741 | Other | TUFTS | |
| 6126042 | Other | MA | CIGNA |
| AA48214 | Other | MA | HPHC |
| 202705274 | Other | MA | UHC |
| 202705274 | Other | MA | GRE AT WEST |
| 7165429 | Other | MA | AETNA |
| 90110 | Other | FHP | |
| 2002299 | Medicaid | MA | |
| J25828 | Other | MA | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 213741 (Massachusetts) | Secondary |
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | 213741 (Massachusetts) | Primary |
| Entity Name | Boston Pain Specialist, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598951543 PECOS PAC ID: 2365471513 Enrollment ID: O20050808000760 |
News Archive
A young pharmacy graduate has been awarded national recognition for her pioneering research in the field of genetics which has the potential to treat diseases such as cancer and Parkinson's.
Researchers at The University of Western Ontario have discovered a strategy for stimulating the formation of highly functional new blood vessels in tissues that are starved of oxygen. Dr. Geoffrey Pickering and Matthew Frontini at the Schulich School of Medicine & Dentistry developed a strategy in which a biological factor, called fibroblast growth factor 9, is delivered at the same time that the body is making its own effort at forming new blood vessels in vulnerable or damaged tissue.
The brains of children who were born just a few weeks early differ from those born on time, and these differences may affect learning and behavior, according to a study to be presented Monday, May 5, at the Pediatric Academic Societies (PAS) annual meeting in Vancouver, British Columbia, Canada.
Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.
In a new study, scientists at the National Institutes of Health took a molecular-level journey into microtubules, the hollow cylinders inside brain cells that act as skeletons and internal highways.
› Verified 3 days ago
| Entity Name | Advanced Pain Management Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770685877 PECOS PAC ID: 9032115746 Enrollment ID: O20061019000362 |
News Archive
A young pharmacy graduate has been awarded national recognition for her pioneering research in the field of genetics which has the potential to treat diseases such as cancer and Parkinson's.
Researchers at The University of Western Ontario have discovered a strategy for stimulating the formation of highly functional new blood vessels in tissues that are starved of oxygen. Dr. Geoffrey Pickering and Matthew Frontini at the Schulich School of Medicine & Dentistry developed a strategy in which a biological factor, called fibroblast growth factor 9, is delivered at the same time that the body is making its own effort at forming new blood vessels in vulnerable or damaged tissue.
The brains of children who were born just a few weeks early differ from those born on time, and these differences may affect learning and behavior, according to a study to be presented Monday, May 5, at the Pediatric Academic Societies (PAS) annual meeting in Vancouver, British Columbia, Canada.
Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.
In a new study, scientists at the National Institutes of Health took a molecular-level journey into microtubules, the hollow cylinders inside brain cells that act as skeletons and internal highways.
› Verified 3 days ago
| Entity Name | Merrimack Valley Pain Management Associates, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962652990 PECOS PAC ID: 5496810707 Enrollment ID: O20090220000450 |
News Archive
A young pharmacy graduate has been awarded national recognition for her pioneering research in the field of genetics which has the potential to treat diseases such as cancer and Parkinson's.
Researchers at The University of Western Ontario have discovered a strategy for stimulating the formation of highly functional new blood vessels in tissues that are starved of oxygen. Dr. Geoffrey Pickering and Matthew Frontini at the Schulich School of Medicine & Dentistry developed a strategy in which a biological factor, called fibroblast growth factor 9, is delivered at the same time that the body is making its own effort at forming new blood vessels in vulnerable or damaged tissue.
The brains of children who were born just a few weeks early differ from those born on time, and these differences may affect learning and behavior, according to a study to be presented Monday, May 5, at the Pediatric Academic Societies (PAS) annual meeting in Vancouver, British Columbia, Canada.
Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.
In a new study, scientists at the National Institutes of Health took a molecular-level journey into microtubules, the hollow cylinders inside brain cells that act as skeletons and internal highways.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rami Rustum, MD 280 Merrimack St, Suite 103, Lawrence, MA 01843-1779 Ph: (978) 685-2455 | Dr Rami Rustum, MD 280 Merrimack St, Suite 103, Lawrence, MA 01843-1779 Ph: (978) 685-2455 |
News Archive
A young pharmacy graduate has been awarded national recognition for her pioneering research in the field of genetics which has the potential to treat diseases such as cancer and Parkinson's.
Researchers at The University of Western Ontario have discovered a strategy for stimulating the formation of highly functional new blood vessels in tissues that are starved of oxygen. Dr. Geoffrey Pickering and Matthew Frontini at the Schulich School of Medicine & Dentistry developed a strategy in which a biological factor, called fibroblast growth factor 9, is delivered at the same time that the body is making its own effort at forming new blood vessels in vulnerable or damaged tissue.
The brains of children who were born just a few weeks early differ from those born on time, and these differences may affect learning and behavior, according to a study to be presented Monday, May 5, at the Pediatric Academic Societies (PAS) annual meeting in Vancouver, British Columbia, Canada.
Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.
In a new study, scientists at the National Institutes of Health took a molecular-level journey into microtubules, the hollow cylinders inside brain cells that act as skeletons and internal highways.
› Verified 3 days ago
Michael C Connelly, M.D. Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 354 Merrimack St Ste 1, Lawrence, MA 01843 Phone: 978-687-2321 Fax: 978-722-7287 |